Phage-assisted evolution of highly active cytosine base editors with enhanced selectivity and minimal sequence context preference
- PMID: 38402281
- PMCID: PMC10894238
- DOI: 10.1038/s41467-024-45969-7
Phage-assisted evolution of highly active cytosine base editors with enhanced selectivity and minimal sequence context preference
Abstract
TadA-derived cytosine base editors (TadCBEs) enable programmable C•G-to-T•A editing while retaining the small size, high on-target activity, and low off-target activity of TadA deaminases. Existing TadCBEs, however, exhibit residual A•T-to-G•C editing at certain positions and lower editing efficiencies at some sequence contexts and with non-SpCas9 targeting domains. To address these limitations, we use phage-assisted evolution to evolve CBE6s from a TadA-mediated dual cytosine and adenine base editor, discovering mutations at N46 and Y73 in TadA that prevent A•T-to-G•C editing and improve C•G-to-T•A editing with expanded sequence-context compatibility, respectively. In E. coli, CBE6 variants offer high C•G-to-T•A editing and no detected A•T-to-G•C editing in any sequence context. In human cells, CBE6 variants exhibit broad Cas domain compatibility and retain low off-target editing despite exceeding BE4max and previous TadCBEs in on-target editing efficiency. Finally, we show that the high selectivity of CBE6 variants is well-suited for therapeutically relevant stop codon installation without creating unwanted missense mutations from residual A•T-to-G•C editing.
© 2024. The Author(s).
Conflict of interest statement
The authors declare competing financial interests: The Broad Institute has filed a patent application on behalf of E.Z., M.E.N., and D.R.L on the base editors developed in this study. D.R.L. is a consultant for Prime Medicine, Beam Therapeutics, Pairwise Plants, Chroma Medicine, and Nvelop Therapeutics, companies that use or deliver agents for genome editing, epigenome engineering, or PACE, and owns equity in these companies. The remaining authors declare no competing interests.
Figures





Similar articles
-
Improving plant C-to-G base editors with a cold-adapted glycosylase and TadA-8e variants.Trends Biotechnol. 2025 Jul;43(7):1765-1787. doi: 10.1016/j.tibtech.2025.03.001. Epub 2025 Apr 4. Trends Biotechnol. 2025. PMID: 40187931
-
Rationally Designed TadA-Derived Cytosine Editors Enable Context-Independent Zebrafish Genome Editing.Adv Sci (Weinh). 2025 Jul 20:e09800. doi: 10.1002/advs.202509800. Online ahead of print. Adv Sci (Weinh). 2025. PMID: 40685751
-
Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity.Nat Biotechnol. 2023 May;41(5):673-685. doi: 10.1038/s41587-022-01533-6. Epub 2022 Nov 10. Nat Biotechnol. 2023. PMID: 36357719 Free PMC article.
-
Antidepressants for chronic non-cancer pain in children and adolescents.Cochrane Database Syst Rev. 2017 Aug 5;8(8):CD012535. doi: 10.1002/14651858.CD012535.pub2. Cochrane Database Syst Rev. 2017. PMID: 28779487 Free PMC article.
-
Yoga for chronic non-specific low back pain.Cochrane Database Syst Rev. 2022 Nov 18;11(11):CD010671. doi: 10.1002/14651858.CD010671.pub3. Cochrane Database Syst Rev. 2022. PMID: 36398843 Free PMC article.
Cited by
-
Multiplexed in vivo base editing identifies functional gene-variant-context interactions.bioRxiv [Preprint]. 2025 Feb 26:2025.02.23.639770. doi: 10.1101/2025.02.23.639770. bioRxiv. 2025. PMID: 40060482 Free PMC article. Preprint.
-
Current trends in gene therapy to treat inherited disorders of the brain.Mol Ther. 2025 May 7;33(5):1988-2014. doi: 10.1016/j.ymthe.2025.03.057. Epub 2025 Apr 2. Mol Ther. 2025. PMID: 40181540 Review.
-
Engineering a bacterial toxin deaminase from the DYW-family into a novel cytosine base editor for plants and mammalian cells.Genome Biol. 2025 Feb 3;26(1):18. doi: 10.1186/s13059-025-03478-w. Genome Biol. 2025. PMID: 39901278 Free PMC article.
-
Establishment and rescue of fibroblast cell lines carrying a nonsense mutation of RB1 by CRISPR-based base editing.Sci Rep. 2025 Jul 11;15(1):25074. doi: 10.1038/s41598-025-10600-2. Sci Rep. 2025. PMID: 40646080 Free PMC article.
-
Clinical development of allogeneic chimeric antigen receptor αβ-T cells.Mol Ther. 2025 Jun 4;33(6):2426-2440. doi: 10.1016/j.ymthe.2025.03.040. Epub 2025 Mar 27. Mol Ther. 2025. PMID: 40156192 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous